Alembic Pharmaceuticals Receives USFDA Approval for Pantoprazole Sodium Injection, Strengthens U.S. Portfolio

Alembic Pharmaceuticals Ltd has been granted final approval by the United States Food and Drug Administration (USFDA) for its Pantoprazole Sodium Injection, another step in the company's drive to build its presence in the U.S. generics market. The approval is for the injectable formulation of Pantoprazole, which is used to treat gastroesophageal reflux disease (GERD) and other acid-related disorders.

 

Key Highlights:

Leadership Views:

Alembic Pharmaceuticals' spokesperson averred, "This approval reinforces our commitment to providing high-quality and cost-effective healthcare solutions worldwide."

 

Outlook

With this addition to its portfolio, Alembic Pharmaceuticals is ready to take a significant part of the U.S. market while it remains committed to innovation and quality.

 

Sources: USFDA Press Release, Economic Times, Business Standard; April 1, 2025